Jump to content

Vemurafenib: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
2over0 (talk | contribs)
17,247 edits
developed → investigated - the molecule exists, they are now trying to figure out how well it works
"developed" is the right term here, drug development as commonly used in the pharmaceutical industry includes human clinical trials
Line 31: Line 31:
{{FixBunching|end}}
{{FixBunching|end}}


'''PLX4032''' is a [[BRAF (gene)|B-Raf]] enzyme inhibitor that is being investigated by [[Plexxikon]] for the treatment of late-stage [[melanoma]].<ref name="pmid20823850">{{PDB|3OG7}}; {{cite journal | author = Bollag G, Hirth P, Tsai J, ''et al.'' | title = Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | journal = Nature | volume = | issue = | pages = | year = 2010 | month = September | pmid = 20823850 | doi = 10.1038/nature09454 | url = | issn = }}</ref>
'''PLX4032''' is a [[BRAF (gene)|B-Raf]] enzyme inhibitor that being [[drug development|developed]] by [[Plexxikon]] for the treatment of late-stage [[melanoma]].<ref name="pmid20823850">{{PDB|3OG7}}; {{cite journal | author = Bollag G, Hirth P, Tsai J, ''et al.'' | title = Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | journal = Nature | volume = | issue = | pages = | year = 2010 | month = September | pmid = 20823850 | doi = 10.1038/nature09454 | url = | issn = }}</ref>


== Mechanism of action ==
== Mechanism of action ==

Revision as of 15:58, 3 October 2010

Template:FixBunching

Vemurafenib
Clinical data
Routes of
administration		Oral
ATC code
Identifiers
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.287.801 Edit this at Wikidata
Chemical and physical data
FormulaC23H18ClF2N3O3S
Molar mass489.92 g/mol g·mol−1

Template:FixBunching

Crystallographic structure of B-Raf (rainbow colored, N-terminus = blue, C-terminus = red) complexed with PLX4032 (spheres, carbon = white, oxygen = red, nitrogen = blue, chlorine = green, fluorine = cyan, sulfur = yellow).[1]

Template:FixBunching

PLX4032 is a B-Raf enzyme inhibitor that being developed by Plexxikon for the treatment of late-stage melanoma.[1]

Mechanism of action

PLX4032 (RO5185426), has been shown to cause programmed cell death in melanoma cell lines.[2] PLX4032 interrupts the B-Raf/MEK step on the B-Raf/MEK/ERK pathway − if the B-Raf has a common mutation.

PLX4032 only works in melanoma patients whose cancer has a V600E BRAF mutation (that is, at amino acid position number 600 on the B-RAF protein, the normal valine is replaced by glutamic acid). About 60% of melanomas have the V600E mutation. Melanoma cells without this mutation are not inhibited by PLX4032; PLX4032 paradoxically stimulates normal BRAF and may promote tumor growth.[3][4]

In vitro, a melanoma cell line A375 is inhibited by silencing the BRAF gene by short hairpin RNA.[2]

Clinical trials

In a phase I clinical study, PLX4032 was able to reduce numbers of cancer cells in over half of a group of 16 patients with advanced melanoma, and the treated group had a median increased survival time of 6 months over the control group.[5][6][7][8] A second phase I study, in patients with a V600E mutation in B-Raf, ~80% showed partial to complete regression. However the regression only lasted from 2 to 18 months.[9]

Phase I[10] and phase II studies are ongoing,[11] and a phase III trial has been started.[12]

References

  1. ^ a b PDB: 3OG7​; Bollag G, Hirth P, Tsai J; et al. (2010). "Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma". Nature. doi:10.1038/nature09454. PMID 20823850. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  2. ^ a b Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C (2008). "BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells". Mol. Cancer Res. 6 (5): 751–9. doi:10.1158/1541-7786.MCR-07-2001. PMID 18458053. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  3. ^ Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S (2010). "RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth". Nature. 464 (7287): 431–5. doi:10.1038/nature08833. PMID 20130576. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  4. ^ Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M (2010). "PLX4032, a Selective BRAF(V600E) Kinase Inhibitor, Activates the ERK Pathway and Enhances Cell Migration and Proliferation of BRAF(WT) Melanoma Cells". Pigment Cell Melanoma Res. 23 (2): 190–200. doi:10.1111/j.1755-148X.2010.00685.x. PMC 2848976. PMID 20149136. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  5. ^ "Drug hope for advanced melanoma". BBC News. 2009-06-02. Retrieved 2009-06-07.
  6. ^ Harmon A (2010-02-21). "Target Cancer - A Roller Coaster Chase for a Cure". NY Times. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  7. ^ Garber K (2009). "Cancer research. Melanoma drug vindicates targeted approach". Science. 326 (5960): 1619. doi:10.1126/science.326.5960.1619. PMID 20019269. {{cite journal}}: Unknown parameter |month= ignored (help)
  8. ^ Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K, Chapman P. "Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. - ASCO". 2009 ASCO Annual Meeting Abstract, J Clin Oncol 27:15s, 2009 (suppl; abstr 9000). {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)CS1 maint: multiple names: authors list (link)
  9. ^ Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010). "Inhibition of mutated, activated BRAF in metastatic melanoma". N. Engl. J. Med. 363 (9): 809–19. doi:10.1056/NEJMoa1002011. PMID 20818844. {{cite journal}}: Unknown parameter |laysource= ignored (help); Unknown parameter |laysummary= ignored (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  10. ^ "Safety Study of PLX4032 in Patients With Solid Tumors - Full Text View -". NCT00405587. ClinicalTrials.gov. 2009-10-28. Retrieved 2010-02-23. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  11. ^ "A Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma". NCT00949702. ClinicalTrials.gov. 2010-02-15. Retrieved 2010-02-23. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
  12. ^ "First Patient Dosed In Phase 3 Trial Of PLX4032 (RG7204) For Metastatic Melanoma". Press Release. Plexxikon. 2010-01-08. Retrieved 2010-03-04. {{cite web}}: Cite has empty unknown parameter: |coauthors= (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Vemurafenib&oldid=388482596"